Published in Cardiovasc Diabetol on March 12, 2014
Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci (2015) 0.81
Associations between recent severe hypoglycemia, retinal vessel diameters, and cognition in adults with type 1 diabetes. J Diabetes Complications (2016) 0.75
The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care (2005) 3.36
Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat (2005) 3.02
Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry (2009) 2.70
Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia (1995) 2.27
Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. Diabetologia (2010) 2.19
Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart (2011) 1.80
Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke (2009) 1.66
Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis (2013) 1.41
Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. Pediatr Diabetes (2006) 1.35
Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes (2009) 1.20
Aortic stiffness is associated with cardiac function and cerebral small vessel disease in patients with type 1 diabetes mellitus: assessment by magnetic resonance imaging. Eur Radiol (2009) 1.14
Resting-state brain networks in type 1 diabetic patients with and without microangiopathy and their relation to cognitive functions and disease variables. Diabetes (2012) 1.13
Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging. Diabetes Care (2011) 1.09
Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol (2008) 1.05
Relationship between carotid intima-media thickness and silent cerebral infarction in Japanese subjects with type 2 diabetes. Diabetes Care (2009) 1.00
Diffusion tensor imaging in type 1 diabetes: decreased white matter integrity relates to cognitive functions. Diabetologia (2012) 0.96
Determinants of carotid artery wall thickening in young patients with Type 1 diabetes mellitus. Diabet Med (1998) 0.87
Carotid-femoral pulse wave velocity is associated with cerebral white matter lesions in type 2 diabetes. Diabetes Care (2012) 0.86
Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. Diabetes Care (2013) 0.85
The association of early atherosclerosis and retinopathy in adolescents with type 1 diabetes: preliminary report. Acta Diabetol (2007) 0.84
Cerebral blood flow and glucose metabolism measured with positron emission tomography are decreased in human type 1 diabetes. Diabetes (2013) 0.83
CD146 deletion in the nervous system impairs appetite, locomotor activity and spatial learning in mice. PLoS One (2013) 0.82
The relationship between early atherosclerosis and endothelial dysfunction in type 1 diabetic patients as evidenced by measurement of carotid intima-media thickness and soluble CD146 levels: a cross sectional study. Cardiovasc Diabetol (2013) 0.80
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care (2005) 5.99
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med (2004) 3.26
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst (2008) 3.13
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12
Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev (2006) 3.06
Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis (2006) 2.95
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol (2003) 2.74
Cognitive deficits in adult patients with brain tumours. Lancet Neurol (2004) 2.71
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care (2007) 2.61
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care (2002) 2.51
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology (2012) 2.44
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol (2009) 2.35
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol (2013) 2.32
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clin Invest (2008) 2.24
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Sleep benefits subsequent hippocampal functioning. Nat Neurosci (2009) 2.05
Different aspects of visual impairment as risk factors for falls and fractures in older men and women. J Bone Miner Res (2004) 2.04
Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism. J Hypertens (2011) 2.04
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Disturbed functional connectivity in brain tumour patients: evaluation by graph analysis of synchronization matrices. Clin Neurophysiol (2006) 1.82
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes (2006) 1.74
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry (2010) 1.68
Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology (2010) 1.68
Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol (2013) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
The confidence in diabetes self-care scale: psychometric properties of a new measure of diabetes-specific self-efficacy in Dutch and US patients with type 1 diabetes. Diabetes Care (2003) 1.65
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol (2002) 1.64
Psychometric properties of vision-related quality of life questionnaires: a systematic review. Ophthalmic Physiol Opt (2004) 1.62
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol (2005) 1.61
Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care (2002) 1.60
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol (2003) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol (2006) 1.55
Birth weight relates to salt sensitivity of blood pressure in healthy adults. Hypertension (2008) 1.55
Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol (2009) 1.54
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2011) 1.54
Diffusion changes predict cognitive and functional outcome: the LADIS study. Ann Neurol (2013) 1.54
Changing the odds. What do we learn from prevention studies targeted at people with a positive family history of type 2 diabetes? Prim Care Diabetes (2011) 1.54
Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol (2005) 1.53
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. Arch Gen Psychiatry (2005) 1.53